Identification of signaling pathways in early mammary gland development by mouse genetics

The mammary gland develops as an appendage of the ectoderm. The prenatal stage of mammary development is hormone independent and is regulated by sequential and reciprocal signaling between the epithelium and the mesenchyme. A number of recent studies using human and mouse genetics, in particular targeted gene deletion and transgenic expression, have identified some of the signals that control specific steps in development. This process involves cell specification and proliferation, reciprocal tissue interactions and cell migration. Since some of these events are recapitulated during tumorigenesis, an understanding of these signaling pathways may contribute to the development of targeted therapies and novel drugs

Cancer Report 2008

Welcome Letter by the Directors of the Cancer Center 2-3 Stories from cancer survivors 4-5 Prostate Cancer 6-7 Kidney Cancer 8 Bladder Cancer 9 Activity Report 10-11 Cancer Research 12-13 Retirees 13 Quality Cancer Care 14-15 Survivorship 16 CLIMB® Program 17 Drive Through Colon Cancer Screening saves lives 18 Generous Gifts Changing Lives 19 Innovative Care 2

Cancer Report 2006

Cancer Registry Analysis of 2006 activity report Chairperson\u27s report Hematopoietic Cancer Repor

Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study.

PURPOSE: Chemotherapy with or without immunotherapy remains the mainstay of treatment for triple-negative breast cancer (TNBC). A subset of TNBCs express the androgen receptor (AR), representing a potential new therapeutic target. This study assessed the feasibility of adjuvant enzalutamide, an AR antagonist, in early-stage, AR-positive (AR +) TNBC. METHODS: This study was a single-arm, open-label, multicenter trial in which patients with stage I-III, AR ≥ 1% TNBC who had completed standard-of-care therapy were treated with enzalutamide 160 mg/day orally for 1 year. The primary objective of this study was to evaluate the feasibility of 1 year of adjuvant enzalutamide, defined as the treatment discontinuation rate of enzalutamide due to toxicity, withdrawal of consent, or other events related to tolerability. Secondary endpoints included disease-free survival (DFS), overall survival (OS), safety, and genomic features of recurrent tumors. RESULTS: Fifty patients were enrolled in this study. Thirty-five patients completed 1 year of therapy, thereby meeting the prespecified trial endpoint for feasibility. Thirty-two patients elected to continue with an optional second year of treatment. Grade ≥ 3 treatment-related adverse events were uncommon. The 1-year, 2-year, and 3-year DFS were 94%, 92% , and 80%, respectively. Median OS has not been reached. CONCLUSION: This clinical trial demonstrates that adjuvant enzalutamide is a feasible and well-tolerated regimen in patients with an early-stage AR + TNBC. Randomized trials in the metastatic setting may inform patient selection through biomarker development; longer follow-up is needed to determine the effect of anti-androgens on DFS and OS in this patient population

Cancer Report 2016

Cancer Registry Statistics 1 Welcome 2-3 Continued Advancement 3 A New Chapter 4-5 Relieving Financial Stress 6 Diagnostic Imaging 7 Neurosurgical Options for Brain Tumors 8-9 Radiation Therapy Options for Brain Cancer 10 Chemotherapy Options for Brain Cancer 10 Clinical Research 11 Palliative Care and Brain Cancer 12-13 Oncology Nursing 14-15 Integrative Therapy Benefits Patients 16 Building a Foundation for Cancer Survivors 17 Surviving with Faith 18-19 Glioblastoma Multiforme Study 20-21 Clinical Achievements back cover Mayo Clinic Cancer Care Network back cove